Other clinical trials investigating these agents include Checkmate 498, a Phase III trial enrolling 550 newly diagnosed, MGMT unmethylated GBM patients comparing nivolumab to TMZ both in combination with RT. The gene discussed is MGMT; the disease is glioblastoma.